Case number 1:22-cv-01474
Ferring Pharmaceuticals Inc. et al v. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 23, 2023 | 37 | NOTICE OF SERVICE of Defendant Jiangsu Hansoh Pharmaceutical Group Co., Ltd.'s Initial Invalidity Contentions Regarding U.S. Patent No. 8,828,938 and accompanying document production JHDEGA003 (Bates range JHDEGA00012463 - JHDEGA00012569) filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd..(Taylor, Daniel) (Entered: 06/23/2023) (2) |
| Jun 23, 2023 | N/A | SO ORDERED re 36 STIPULATION TO EXTEND TIME for Substantial Completion of Document Production from June 23, 2023 to July 7, 2023. ORDERED by Judge Maryellen Noreika on 6/23/2023. (dlw) (Entered: 06/23/2023) (0) |
| Jun 23, 2023 | 36 | STIPULATION TO EXTEND TIME for Substantial Completion of Document Production from June 23, 2023 to July 7, 2023 - filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. (Taylor, Daniel) (Entered: 06/23/2023) (2) |
| Jun 9, 2023 | 35 | NOTICE OF SERVICE of (1) Plaintiffs' First Set of Requests for Admission (Nos. 1-19); (2) Plaintiffs' First Set of Interrogatories (Nos. 1-12), and (3) Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-37) filed by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S.(Bourke, Mary) (Entered: 06/09/2023) (2) |
| Jun 5, 2023 | 34 | NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Jiangsu Hansoh Pharmaceutical Group Co., Ltd.'s First Set of Interrogatories (Nos. 1-6), and (2) Plaintiffs' Objections and Responses to Defendant's First Set of Requests for Production (Nos. 1-78) filed by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S.(Bourke, Mary) (Entered: 06/05/2023) (2) |
| Jun 2, 2023 | N/A | SO ORDERED re 33 STIPULATION TO EXTEND TIME for Substantial Completion of Document Production from June 9, 2023 to June 23, 2023. ORDERED by Judge Maryellen Noreika on 6/2/2023. (dlw) (Entered: 06/02/2023) (0) |
| Jun 2, 2023 | 33 | STIPULATION TO EXTEND TIME for Substantial Completion of Document Production from June 9, 2023 to June 23, 2023 - filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. (Taylor, Daniel) (Entered: 06/02/2023) (2) |
| May 12, 2023 | 32 | NOTICE OF SERVICE of Plaintiffs' Initial Infringement Contentions filed by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S.(Severance, Dana) (Entered: 05/12/2023) (2) |
| May 5, 2023 | 31 | NOTICE OF SERVICE of First Set of Requests for Production of Documents and Things (Nos. 1 - 78) and First Set of Interrogatories (Nos. 1 - 6) filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd..(Taylor, Daniel) (Entered: 05/05/2023) (2) |
| Apr 25, 2023 | 30 | STIPULATION AND ORDER ON DISCOVERY. Signed by Judge Maryellen Noreika on 4/25/2023. (dlw) (Entered: 04/25/2023) (11) |
| Apr 25, 2023 | 29 | STIPULATED PROTECTIVE ORDER. Signed by Judge Maryellen Noreika on 4/25/2023. (dlw) (Entered: 04/25/2023) (26) |
| Apr 24, 2023 | 28 | STIPULATION and Order on Discovery by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S. (Severance, Dana) (Entered: 04/24/2023) (11) |
| Apr 24, 2023 | 27 | PROPOSED ORDER // Stipulated Protective Order by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S. (Severance, Dana) Modified on 4/25/2023 (dlw). (Entered: 04/24/2023) (26) |
| Apr 17, 2023 | 26 | NOTICE OF SERVICE of (1) Plaintiffs' Rule 26(a)(1)(A) Disclosures and (2) Paragraph 3 Disclosures Pursuant to the Delaware Default Standard for Discovery filed by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S.(Severance, Dana) (Entered: 04/17/2023) (2) |
| Apr 17, 2023 | 25 | NOTICE OF SERVICE of Defendant Jiangsu Hansoh Pharmaceutical Group Co., Ltd.'s Initial Disclosures Pursuant to Federal Rule of Civil Procedure 26(a)(1) and Paragraph 3 of the Delaware Default Standard for Discovery filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd..(Belgam, Neal) (Entered: 04/17/2023) (2) |
| Apr 12, 2023 | 24 | SCHEDULING ORDER: Joinder of Parties due by 6/23/2023. Amended Pleadings due by 6/23/2023. Fact Discovery completed by 8/18/2023. Opening Expert Reports due by 1/12/2024. Rebuttal Expert Reports due by 2/16/2024. Reply Expert Reports due by 3/15/2024. Expert Discovery due by 4/12/2024. Daubert Motions due by 4/26/2024. Claim Construction Opening Brief served by 9/29/2023. Claim Construction Answering Brief served by 10/18/2023. Claim Construction Reply Brief served by 11/3/2023. Claim Construction Surreply Brief served by 11/17/2023. Joint Claim Construction Brief filed by 11/21/2023. A Markman Hearing is set for 12/13/2023 at 02:00 PM in Courtroom 4A before Judge Maryellen Noreika. A Pretrial Conference is set for 7/1/2024 at 10:00 AM in Courtroom 4A before Judge Maryellen Noreika. A 4-day Bench Trial is set for 7/15/2024 at 09:00 AM in Courtroom 4A before Judge Maryellen Noreika. Signed by Judge Maryellen Noreika on 4/12/2023. (dlw) (Entered: 04/12/2023) (15) |
| Apr 11, 2023 | 23 | SO ORDERED re 21 Stipulation and Order to Stay - IT IS HEREBY ORDERED that this litigation is bifurcated. The July 15, 2024 trial is limited to validity and infringement of the asserted claims of the '938 patent. This litigation is stayed with respect to the infringement and validity of asserted claims 3 and 13 of the '359 patent, claims 16 and 26 of the '739 patent, claims 3, 5, 8 and 14 of the '870 patent, claim 2 of the '085 patent, and claim 2 of the '398 patent. SEE STIPULATION FOR FURTHER AND COMPLETE DETAILS. Signed by Judge Maryellen Noreika on 4/11/2023. (dlw) (Entered: 04/11/2023) (6) |
| Apr 5, 2023 | 22 | PROPOSED ORDER // Scheduling Order by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S. (Severance, Dana) Modified on 4/5/2023 (dlw). (Entered: 04/05/2023) (15) |
| Apr 5, 2023 | 21 | STIPULATION and Proposed Order to Stay by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S. (Severance, Dana) (Entered: 04/05/2023) (6) |
| Apr 3, 2023 | 20 | NOTICE of Appearance by Daniel Taylor on behalf of Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Taylor, Daniel) (Entered: 04/03/2023) (1) |
| Mar 30, 2023 | N/A | SO ORDERED re 19 STIPULATION TO EXTEND TIME for the Parties to submit the Proposed Scheduling Order to April 5, 2023. ORDERED by Judge Maryellen Noreika on 3/30/2023. (dlw) (Entered: 03/30/2023) (0) |
| Mar 29, 2023 | 19 | STIPULATION TO EXTEND TIME for the Parties to submit the Proposed Scheduling Order to April 5, 2023 - filed by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S. (Bourke, Mary) (Entered: 03/29/2023) (2) |
| Mar 22, 2023 | 18 | STIPULATION TO EXTEND TIME for the Parties to submit the Proposed Scheduling Order from March 22, 2023 to March 29, 2023 - filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. (Belgam, Neal) (Entered: 03/22/2023) (2) |
| Mar 22, 2023 | N/A | SO ORDERED re 18 STIPULATION TO EXTEND TIME for the Parties to submit the Proposed Scheduling Order from March 22, 2023 to March 29, 2023. ORDERED by Judge Maryellen Noreika on 3/22/2023. (dlw) (Entered: 03/22/2023) (0) |
| Mar 17, 2023 | 17 | NOTICE of Withdrawal of Appearance of Delaware Counsel, Eve Ormerod by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Ormerod, Eve) (Entered: 03/17/2023) (1) |
| Mar 15, 2023 | 16 | STIPULATION TO EXTEND TIME for the parties to submit the proposed scheduling order from March 15, 2023 to March 22, 2023 - filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. (Belgam, Neal) (Entered: 03/15/2023) (2) |
| Mar 15, 2023 | N/A | SO ORDERED re 16 STIPULATION TO EXTEND TIME for the parties to submit the proposed scheduling order from March 15, 2023 to March 22, 2023. ORDERED by Judge Maryellen Noreika on 3/15/2023. (dlw) (Entered: 03/15/2023) (0) |
| Feb 14, 2023 | N/A | Pro Hac Vice Attorney H. Howard Wang for Jiangsu Hansoh Pharmaceutical Group Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/14/2023) (0) |
| Feb 13, 2023 | N/A | SO ORDERED re 14 MOTION for Pro Hac Vice Appearance of Attorney H. Howard Wang filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ORDERED by Judge Maryellen Noreika on 2/13/2023. (dlw) (Entered: 02/13/2023) (0) |
| Feb 13, 2023 | 15 | ORAL ORDER - IT IS HEREBY ORDERED that, within thirty (30) days from the date of this Order, the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposed order, which is also consistent with the following guidance. The Bench trial will be set for 7/15/2024. The parties shall provide final contentions (i.e., final infringement and invalidity contentions, as well as final non-infringement and validity contentions) around the time that fact discovery closes (i.e., several weeks prior to or after the deadline to complete fact discovery) and at least three weeks before Plaintiffs serves their opening claim construction brief. Final contentions shall include a party's contentions under its proposed construction(s), as well as under the opposing construction(s) (if such an alternative contention exists). As such, the parties are encouraged to exchange proposed claim terms and proposed constructions early in the case but in no event later than necessary to allow the parties to include alternative contentions in their final contentions. The joint claim construction chart shall be due one week after the parties have completed their exchange of final contentions, and the joint claim construction brief must be filed at least three weeks before the claim construction hearing. The parties shall leave at least three weeks between the claim construction hearing and the opening of expert discovery. The parties are to use the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Noreika, Forms), and the parties must include a proposal for the length and timing of trial. If there are disputes or issues that the Court needs to address in the proposed scheduling order, the parties shall direct the Court to the paragraph numbers in which those appear in a cover letter to the Court. ORDERED by Judge Maryellen Noreika on 2/13/2023. (dlw) (Entered: 02/13/2023) (0) |
| Feb 10, 2023 | 14 | MOTION for Pro Hac Vice Appearance of Attorney H. Howard Wang - filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. (Belgam, Neal) (Entered: 02/10/2023) (3) |
| Feb 10, 2023 | 13 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. (Ormerod, Eve) (Entered: 02/10/2023) (1) |
| Feb 10, 2023 | 12 | ANSWER to 1 Complaint with Additional Defenses by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Ormerod, Eve) Modified on 2/10/2023 (dlw). (Entered: 02/10/2023) (30) |
| Jan 10, 2023 | N/A | SO ORDERED re 11 STIPULATION TO EXTEND TIME for Defendant Jiangsu Hansoh Pharmaceutical Group Co., Ltd. to answer, move, or otherwise respond to the Complaint to February 10, 2023 (Set/Reset Answer Deadlines: Jiangsu Hansoh Pharmaceutical Group Co., Ltd. answer due 2/10/2023). ORDERED by Judge Maryellen Noreika on 1/10/2023. (dlw) (Entered: 01/10/2023) (0) |
| Jan 10, 2023 | 11 | STIPULATION TO EXTEND TIME for Defendant Jiangsu Hansoh Pharmaceutical Group Co., Ltd. to answer, move, or otherwise respond to the Complaint to February 10, 2023 - filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. (Ormerod, Eve) (Entered: 01/10/2023) (2) |
| Jan 10, 2023 | 10 | NOTICE OF SUBSTITUTION OF COUNSEL re Jiangsu Hansoh Pharmaceutical Group Co., Ltd.: Entry of appearance of attorney Neal C. Belgam. Attorney Dominick T. Gattuso terminated. (Belgam, Neal) (Entered: 01/10/2023) (1) |
| Dec 7, 2022 | N/A | Pro Hac Vice Attorney Kyle C. Musgrove for Jiangsu Hansoh Pharmaceutical Group Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr) (Entered: 12/07/2022) (0) |
| Dec 1, 2022 | N/A | Pro Hac Vice Attorney Elizabeth M. Crompton for Jiangsu Hansoh Pharmaceutical Group Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 12/01/2022) (0) |
| Nov 30, 2022 | N/A | SO ORDERED re 9 MOTION for Pro Hac Vice Appearance of Attorney C. Kyle Musgrove and Elizabeth M. Crompton, each of the law firm of Parker Poe Adams & Bernstein, LLP filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ORDERED by Judge Maryellen Noreika on 11/30/2022. (dlw) (Entered: 11/30/2022) (0) |
| Nov 30, 2022 | 9 | MOTION for Pro Hac Vice Appearance of Attorney C. Kyle Musgrove and Elizabeth M. Crompton, each of the law firm of Parker Poe Adams & Bernstein, LLP - filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. (Gattuso, Dominick) (Entered: 11/30/2022) (5) |
| Nov 30, 2022 | N/A | SO ORDERED re 8 STIPULATION TO EXTEND TIME for Hansoh to answer, move or otherwise respond to the Complaint to January 11, 2023 (Set/Reset Answer Deadlines: Jiangsu Hansoh Pharmaceutical Group Co., Ltd. answer due 1/11/2023). ORDERED by Judge Maryellen Noreika on 11/30/2022. (dlw) (Entered: 11/30/2022) (0) |
| Nov 30, 2022 | 8 | STIPULATION TO EXTEND TIME for Hansoh to answer, move or otherwise respond to the Complaint to January 11, 2023 - filed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. (Gattuso, Dominick) (Entered: 11/30/2022) (2) |
| Nov 16, 2022 | N/A | Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) (Entered: 11/16/2022) (0) |
| Nov 10, 2022 | 7 | AFFIDAVIT of Service for Summons, Complaint and related papers served on Jiangsu Hansoh Pharmaceutical Group Co., Ltd. on November 10, 2022, filed by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Bourke, Mary) (Entered: 11/10/2022) (Exhibit 2) (2) |
| Nov 10, 2022 | 7 | AFFIDAVIT of Service for Summons, Complaint and related papers served on Jiangsu Hansoh Pharmaceutical Group Co., Ltd. on November 10, 2022, filed by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Bourke, Mary) (Entered: 11/10/2022) (Main Document) (2) |
| Nov 10, 2022 | 7 | AFFIDAVIT of Service for Summons, Complaint and related papers served on Jiangsu Hansoh Pharmaceutical Group Co., Ltd. on November 10, 2022, filed by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Bourke, Mary) (Entered: 11/10/2022) (Exhibit 1) (3) |
| Nov 9, 2022 | 6 | Summons Issued as to Jiangsu Hansoh Pharmaceutical Group Co., Ltd. on 11/9/2022. (mkr) (Entered: 11/09/2022) (2) |
| Nov 9, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Polypeptide Laboratories Holding AB for Polypeptide Laboratories A/S; Corporate Parent Ferring Holding Inc. for Ferring B.V., Ferring Pharmaceuticals Inc. filed by Ferring B.V., Ferring International Center S.A., Ferring Pharmaceuticals Inc., Polypeptide Laboratories A/S. (mkr) (Entered: 11/09/2022) (2) |
| Nov 9, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,579,359; US 9,415,085; US 8,828,938; US 10,695,398; US 10,729,739; and US 10,973,870. (mkr) (Entered: 11/09/2022) (2) |
| Nov 9, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 9/27/2022. Date of Expiration of Patent: 2/10/2029, 4/27/2032, and 11/5/2030. Thirty Month Stay Deadline: 03/27/2025 (mkr) Modified on 11/16/2022 (dlw). (Entered: 11/09/2022) (2) |
| Nov 9, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) (Entered: 11/09/2022) (3) |
| Nov 9, 2022 | 1 | COMPLAINT filed against Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Filing fee $402, receipt number ADEDC-4002095.) - filed by Polypeptide Laboratories A/S, Ferring Pharmaceuticals Inc., Ferring B.V., and Ferring International Center S.A. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(mkr) (Entered: 11/09/2022) (Exhibit A) (30) |
| Nov 9, 2022 | 1 | COMPLAINT filed against Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Filing fee $402, receipt number ADEDC-4002095.) - filed by Polypeptide Laboratories A/S, Ferring Pharmaceuticals Inc., Ferring B.V., and Ferring International Center S.A. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(mkr) (Entered: 11/09/2022) (Exhibit B) (30) |
| Nov 9, 2022 | 1 | COMPLAINT filed against Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Filing fee $402, receipt number ADEDC-4002095.) - filed by Polypeptide Laboratories A/S, Ferring Pharmaceuticals Inc., Ferring B.V., and Ferring International Center S.A. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(mkr) (Entered: 11/09/2022) (Exhibit C) (30) |
| Nov 9, 2022 | 1 | COMPLAINT filed against Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Filing fee $402, receipt number ADEDC-4002095.) - filed by Polypeptide Laboratories A/S, Ferring Pharmaceuticals Inc., Ferring B.V., and Ferring International Center S.A. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(mkr) (Entered: 11/09/2022) (Exhibit D) (30) |
| Nov 9, 2022 | 1 | COMPLAINT filed against Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Filing fee $402, receipt number ADEDC-4002095.) - filed by Polypeptide Laboratories A/S, Ferring Pharmaceuticals Inc., Ferring B.V., and Ferring International Center S.A. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(mkr) (Entered: 11/09/2022) (Exhibit E) (30) |
| Nov 9, 2022 | 1 | COMPLAINT filed against Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Filing fee $402, receipt number ADEDC-4002095.) - filed by Polypeptide Laboratories A/S, Ferring Pharmaceuticals Inc., Ferring B.V., and Ferring International Center S.A. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(mkr) (Entered: 11/09/2022) (Exhibit F) (7) |
| Nov 9, 2022 | 1 | COMPLAINT filed against Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Filing fee $402, receipt number ADEDC-4002095.) - filed by Polypeptide Laboratories A/S, Ferring Pharmaceuticals Inc., Ferring B.V., and Ferring International Center S.A. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(mkr) (Entered: 11/09/2022) (Exhibit G) (21) |
| Nov 9, 2022 | 1 | COMPLAINT filed against Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Filing fee $402, receipt number ADEDC-4002095.) - filed by Polypeptide Laboratories A/S, Ferring Pharmaceuticals Inc., Ferring B.V., and Ferring International Center S.A. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(mkr) (Entered: 11/09/2022) (Civil Cover Sheet) (2) |
| Nov 9, 2022 | 1 | COMPLAINT filed against Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Filing fee $402, receipt number ADEDC-4002095.) - filed by Polypeptide Laboratories A/S, Ferring Pharmaceuticals Inc., Ferring B.V., and Ferring International Center S.A. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(mkr) (Entered: 11/09/2022) (Main Document) (27) |
